Decision-making on
FP7 work programmes
and calls
European Commission
Research and Inovation DG,
Directorate F Health
Grigorij Kogan
EKHA Meeting, Brussels 23/01/2012
07/04/2015
1
EU support
for Research and Innovation
07/04/2015
The €50 billion Seventh Framework
Programme (FP7, 2007-2013) supports
basic and applied research activities,
still far from the market, offers money and
concentrates
resources
on
strategic
research areas, always on the basis of
technological and scientific excellence.
The broad objectives of FP7 have been
grouped into four categories:
Cooperation
Ideas
People
Capacities
For each type of objective, there is a
specific programme corresponding to the
main areas of EU research policy. All
specific programmes work together to
promote and encourage the creation of
European poles of (scientific) excellence
2
FP7 budget (2007-2013):
€55 billion
= ~6% of public R&D
investment in Europe
07/04/2015
3
Cooperation programme:
thematic areas (€32.4 billion)
07/04/2015
4
http://bookshop.europa.eu/eubookshop/publicationDetails.action?pubuid=593335&offset=0
07/04/2015
5
FP7 Health Programme
- structure
pillar 1:
pillar 2:
pillar 3:
Biotechnology,
generic tools
& technologies
for health
Translating
research for
human health
Optimising
the delivery
of health care
cross-cutting issues: child health, the health of ageing population
gender-related health issues
Activity (Pillar) 4: Other actions across the theme
07/04/2015
6
Collaborative research
in the Health theme
Main policy drivers:
 Improving health of European citizens

Increasing competitiveness of European healthrelated industries and businesses

Addressing global health issues,
including emerging epidemics
07/04/2015
7
Collaborative research
at European level
across borders and other barriers
● between countries:
 multinational consortia, with at least 3 partners from 27 EU
Member States (MS) and / or Associated Countries (AC)
e.g.: Albania, Croatia, FYR Macedonia, Iceland, Israel,
Liechtenstein, Montenegro, Norway, Serbia, Switzerland,
Turkey.
 researchers from any country in the world can participate,
from industrialised countries and from developing countries.
e.g.: Argentina, Australia, Brazil, Canada, China, India, Japan,
Korea, New-Zealand, Russia, South-Africa, USA…
● between different types of organizations
Public & private sector: universities, research centres, large
companies, Small and medium-sized enterprises (SMEs), etc.
● between disciplines: multidisciplinary, translational
07/04/2015
8
Collaborative research
in the Health theme
1: Biotechnology, generic tools and
technologies
 High-throughput research
 Detection, diagnosis and monitoring
 Predicting suitability, safety and efficacy of
therapies
 Innovative therapeutic approaches and
interventions
07/04/2015
9
Collaborative research
in the Health theme
2: Translating research for human health
 Integrating biological data and processes:
large-scale data gathering, systems biology
 Research on the brain and related diseases,
human development and ageing
 Translational research in major infectious
diseases
 Translational research in other major diseases
07/04/2015
10
Collaborative research
in the Health theme
3: Optimising the delivery of healthcare
 Translating clinical research into clinical
practice
 Quality, efficiency and solidarity of healthcare
systems
 Enhanced health promotion and disease
prevention
07/04/2015
11
Collaborative research
in the Health theme
4. Actions across the Theme
 Coordination & Support Actions across the theme
 Responding to EU policy needs
 Specific International Cooperation Actions
(SICAs)
07/04/2015
12
FP7 Cooperation Work
Programme: Health-2012
07/04/2015
13
Two-stage submission and
evaluation procedure
Timetable
Publication of call FP7-HEALTH-2012-INNOVATION-2
20 July 2011
Deadline for submission of stage 1 outline proposals
27 September 2011
Evaluation of stage 1 outline proposals
October 2011
ESRs sent to outline proposal coordinators (“initial information letters”, including
invitation letters to successful applicants)
November 4, 2011
Deadline for submission of stage 2 full proposals
13 December 2011
Evaluation of stage 2 full proposals
January 2012
Ethical screening
By February 3, 2012
Invitation letter to successful coordinators to launch grant agreement negotiations
with Commission services
By February , 2012
Negotiation kick-off meeting in Brussels
February 13, 2012
Signature of first grant agreements
April 2012
07/04/2015
14
Funding schemes
in the Health theme
Funding schemes
limits
partners
Large-scale integrating project (CP-IP)
≥ €6m ≤ €12m
≥3
Network of Excellence (NoE)
≤ €12m
≥3
Small- or medium-scale focussed
research project (CP-FP)
≤ €3m or €6m
≥3
Coordination action (CA)*
≤ €1.5m
≥3
Support action (SA)*
≤ €0.5m
≥1
* for CAs and SAs there are some exceptions.
07/04/2015
15
Policy dimensions:
Industry (SME) participation
& International Cooperation
Emphasis and special measures for:
 Small & Medium-sized Enterprises (SMEs)
 Opportunities and support measures
 International Cooperation
 the possibility to tackle issues on a
global scale
07/04/2015
 an opportunity to extend networks
beyond Europe
16
Who prepares the work programmes for the
● The EU Commission
Research Priorities
 Collects ideas for the preparation of the annual FP7 work program
 Drafts the (annual) FP7 work plans
 Within the EU Commission Scientific Officers (SO) are responsible for the
preparatory work
o Advisory Groups (AG)
 Have been set up by the EU Commission for each of the FP7 themes
 They provide consistent, consolidated advice for the work program
 Members sit on the AG in their personal capacity and do not represent any
organisation or country
o National Contact Points (NCPs)
 Are main providers of advice and individual assistance in all Member States and
Associated States
 Have been set up by the Member or Associated States so the type and level of
services offered may differ from country to country
o
Programme Committees (PCs)

Play an important role at the end of the preparation process of each work
program.
They have to give their approval for all the work programmes that have been
prepared by he EU Commission.
Are involved quite early in the preparation process to insure that the preparation
procedure works quick and smooth


07/04/2015
17
Scientific excellence
at European level
From policy to funding the best research projects:
● The policy for Health research is described in the FP7 specific
programme (available on CORDIS
http://cordis.europa.eu/home_en.html)
● Each year, a work programme is prepared by the EC, in
consultation with a scientific Advisory Group and with the
Programme Committee
● Through calls for proposals the EC invites researchers from all
Europe and beyond to submit their proposals
● The very best projects are selected on the basis of evaluation by
independent experts (peer review)
● After negotiation of a grant agreement, a project is funded for 25 years
07/04/2015
18
Submission & evaluation
Basic principles:
 annual calls for proposals
 eligibility (scope, partners, funding limits, deadline)
 evaluation by panels of independent experts
 overseen by Independent Observers
 3 criteria:
 Science & Technology excellence
 Implementation & Management
 Potential Impact
 feedback: Evaluation Summary Reports (ESRs)
07/04/2015
19
Budget (million)
Annual calls for proposals
in the Health Theme
€ 800

€ 600
 2nd call (2008 budget): € 577 million
€ 400
€ 200
€0
1st call 2007
2nd call 2008
3rd call 2009
4th call 2010
5th call 2011
6th call 2012
7th call 2013





1st call (2007 budget): € 641 million
3rd call (2009 budget): € 610 million
4th call (2010 budget): € 660 million
5th call (2011 budget): € 650 million
6th call (2012 budget): ~ € 645 million
7th call (2013 budget): ~
Call
07/04/2015
20
The Innovative Medicines Initiative (IMI):
the Largest PPP in Life Sciences R&D
http://www.imi.europa.eu/
Why Public-Private
Partnership?
• Innovative medicines require
in-depth knowledge of disease
pathways and molecular
targets
• Anticipating potential side
effects of new drugs is a must
• The pharmaceutical industry
builds new business models
based on collaboration and
transparency
Key Concepts
Underlying
IMI Projects:
• Pre-competitive
research
• Open innovation
Four Calls
published since
2008:
• 23 projects
funded
• Over € 450
million committed
21
07/04/2015
21
Coverage of Kidney Diseases in FP7
Pillar IDEAS – ERC (European Research Council):
4 projects with € 6,813,200 EU Contribution
Pillar COOPERATION HEALTH: 7 projects with € 46,188,148 EU Contribution
INFSO: 2 projects with € 8,759,140 EU Contribution
Pillar PEOPLE – 13 projects with € 9,872,575 EU Contribution
Total EU Contribution - € 71,633,063
07/04/2015
22
07/04/2015
23
Contacts & Information
FP7 Health web site:
http://cordis.europa.eu/fp7/health
NCPs:
http://cordis.europa.eu/fp7/health/support_en.html
Registration as an Expert:
https://cordis.europa.eu/emmfp7/
FP7 calls: http://cordis.europa.eu/fp7/dc
Health projects database: www.healthcompetence.eu
SMEsgoHealth: www.smesgohealth.org
07/04/2015
24
The Health Directorate
Director – Dr. Ruxandra Draghia-Akli:
Medical Research unit (F2)
Head of unit: Maria Vidal-Ragout (maria-jose.vidal-ragout@ec.europa.eu)
Deputy Head of Unit: Karim Berkouk (karim.berkouk@ec.europa.eu)
Infectious Diseases unit (F3)
Head of unit: Line Mathiessen (line.mathiessen@ec.europa.eu)
Deputy Head of unit: Anna Lönnroth (anna.lonnroth@ec.europa.eu)
Avanced Therapies and Systems Medicine unit (F4)
Head of unit: Arnd Hoeveler (arnd.hoeveler@ec.europa.eu)
Deputy Head of unit: Bernard Mulligan (bernard.mulligan@ec.europa.eu)
Personalized Medicine unit (F5)
Head of unit: Patrik Kolar (patrik.kolar@ec.europa.eu)
Deputy Head of unit: Irene Norstedt (irene.norstedt@ec.europa.eu)
Horizontal Aspects unit (F1)
Head of unit: Stéphane Hogan
(stephane.hogan@ec.europa.eu)
Administration & Finance unit (F6)
Head of unit: Georgios Zisimatos
(georgios.zisimatos@ec.europa.eu)
07/04/2015
25
What is Horizon 2020
07/04/2015
26
THANK YOU
FOR YOUR ATTENTION!
Grigorij Kogan « Chronic Diseases »
Unit F-2 Medical Research
Directorate F « Health »
DG Research and Innovation
European Commission
grigorij.kogan@ec.europa.eu
07/04/2015
27